SVB Leerink lowers Calithera Biosciences [CALA] rating to Market Perform and sets price target at $2
SVB Leerink took its Calithera Biosciences [CALA] rating to the equivalent of Market Perform from Outperform, and the price target to $2, in a research note dated 2021-01-05. Some new analysts also started their coverage, with H.C. Wainwright’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in mid […]
